Join Growin Stock Community!

Zynex, inc.ZYXI.US Overview

US StockHealthcare
(No presentation for ZYXI)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

ZYXI AI Insights

ZYXI Overall Performance

ZYXI AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

ZYXI Recent Performance

-

Zynex, inc.

0.05%

Avg of Sector

-0.31%

S&P500

ZYXI PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

ZYXI Key Information

ZYXI Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

ZYXI Profile

Zynex, Inc., through its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography triggered electrical stimulation device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; and E-Wave, an NMES device. It also supplies private labeled products, including electrodes for the delivery of electrical current to the body, and batteries for use in electrotherapy products. In addition, the company distributes Comfortrac/Saunders for cervical traction, JetStream for hot/cold therapy, LSO Back Braces for lumbar support, and knee braces for knee support. Further, it offers Zynex Fluid Monitoring System (CM-1500), a fluid volume monitor, which is a non-invasive medical device for monitoring relative fluid volume changes used in operating and recovery rooms to detect fluid loss during surgery and internal bleeding during recovery; Zynex Wireless Fluid Monitoring System (CM-1600), a noninvasive monitoring device designed to measure relative changes in fluid volume in adult patients; NiCO CO-Oximeter, a laser-based noninvasive co-oximeter; and HemeOx tHb Oximeter, a laser-based total hemoglobin pulse oximeter. The company provides its products for use in pain management and control; stroke and spinal cord injury rehabilitation; hemodynamic monitoring; and pulse oximetry monitoring. It sells its products through direct sales force primarily in the United States. Zynex, Inc. was founded in 1996 and is headquartered in Englewood, Colorado.

Price of ZYXI

ZYXI FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

ZYXI Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-2.43
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
0.04
PB Ratio
34.84
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
71.64%
Net Margin
-68.35%
Revenue Growth (YoY)
-44.13%
Profit Growth (YoY)
-49.65%
3-Year Revenue Growth
-31.47%
3-Year Profit Growth
-37.52%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-2.43
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
0.04
PB Ratio
34.84
Price-to-FCF
-
Gross Margin
71.64%
Net Margin
-68.35%
Revenue Growth (YoY)
-44.13%
Profit Growth (YoY)
-49.65%
3-Year Revenue Growth
-31.47%
3-Year Profit Growth
-37.52%

  • When is ZYXI's latest earnings report released?

    The most recent financial report for Zynex, inc. (ZYXI) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating ZYXI's short-term business performance and financial health. For the latest updates on ZYXI's earnings releases, visit this page regularly.

  • What is the operating profit of ZYXI?

    According to the latest financial report, Zynex, inc. (ZYXI) reported an Operating Profit of -43.96M with an Operating Margin of -329.06% this period, representing a decline of 1,256.29% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is ZYXI's revenue growth?

    In the latest financial report, Zynex, inc. (ZYXI) announced revenue of 13.36M, with a Year-Over-Year growth rate of -73.26%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much debt does ZYXI have?

    As of the end of the reporting period, Zynex, inc. (ZYXI) had total debt of 71.62M, with a debt ratio of 1.58. Short-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does ZYXI have?

    At the end of the period, Zynex, inc. (ZYXI) held Total Cash and Cash Equivalents of 13.57M, accounting for 0.3 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does ZYXI go with three margins increasing?

    In the latest report, Zynex, inc. (ZYXI) did not achieve the “three margins increasing” benchmark, with a gross margin of 60.5%%, operating margin of -329.06%%, and net margin of -321.2%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess ZYXI's profit trajectory and future growth potential.

  • Is ZYXI's EPS continuing to grow?

    According to the past four quarterly reports, Zynex, inc. (ZYXI)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -1.42. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of ZYXI?

    Zynex, inc. (ZYXI)'s Free Cash Flow (FCF) for the period is -6.33M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 190.35% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of ZYXI?

    The latest valuation data shows Zynex, inc. (ZYXI) has a Price-To-Earnings (PE) ratio of -0.23 and a Price/Earnings-To-Growth (PEG) ratio of -0. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.